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OBJECTIVE: To determine whether the incidence of fe-
brile leucopenia (FL) is reduced in SCLC patients by ad-
ministering prophylactic antibiotics thereby reducing re-
source use and costs associated with treatment.
METHODS: A cost-effectiveness analysis was conducted
alongside a multicenter phase III randomized controlled
trial with a 2  2 factorial design. The trial was designed to
compare standard dose CDE (cyclophosphamide, dox-
orubucin and etoposide) versus intensified CDE (125%
dose with G-CSF), with or without prophylactic antibiot-
ics. Patients in the verum arm received roxithromycin
150 mg and ciprofloxacin 750 mg, both given twice daily
for 10 days, commencing the day after completing each
cycle of chemotherapy. The economic evaluation examines
the costs and effects of patients taking antibiotics versus
placebo. Results are presented for 33 patients in The Neth-
erlands, representing 20.5% of the total sample (n  161).
Resource utilization data were collected during the trial
and included hospitalizations, concomitant medications,
transfusions and medical procedures. The viewpoint of the
health insurance system is taken, using 1998 prices ex-
pressed in Dutch guilders (ppp of 2.07NLG/US$). The ef-
fectiveness measures include the incidence of febrile leu-
copenia and the number of infectious deaths.
RESULTS: The average cost attributed to patients in the
placebo arm was 12,898 NLG compared to 6,999 NLG in
the verum arm, yielding a difference of 5,899 NLG (US$
2850) (95% CI () 2081  13,897) in favor of administer-
ing prophylactic antibiotics. The clinical trial (n  161)
demonstrated a 50% decrease in the incidence of FL and an
absolute reduction in the risk of infectious death from 6%
to 0% in patients taking antibiotics.
CONCLUSION: The use of prophylactic antibiotics in
small cell lung cancer patients is cost-effective as it reduces
the incidence of FL and infectious deaths whilst reducing
direct medical costs by 45%. This study was partly spon-
sored by Bayer BV.
CA2
COST COMPARISONS BETWEEN HOSPITALS
IN DIFFERENT COUNTRIES BY MEANS OF A 
RESOURCE USE INDEX
Neymark N, Adriaenssen I
EORTC Health Economics Unit, Brussels, Belgium
OBJECTIVES: To compare the direct costs of managing
patients with advanced colorectal cancer in five European
countries by means of a resource use index, which avoids
the confounding caused by differences in absolute and rela-
tive prices.
METHODS: In 10 hospitals in five countries, data on pa-
tient management and resource use were collected from the
hospital charts of 20 consecutive, newly diagnosed pa-
tients. All available data on resource use for each patient
from diagnosis until death or last seen alive were included
in the investigation. For only one country, Belgium, was it
possible to find a complete set of consistent unit prices,
namely the tariffs according to which the providers are re-
munerated by the health insurance system. By using these
unit prices to value the use of resources in all countries, an
index for average total resource use per hospital has been
constructed, which reflects only differences in real resource
utilization. The average across all the hospitals has been set
equal to 100, so index values represent deviations from this
average.
RESULTS: The estimated index values for average total re-
source use vary from 75 to 131. Differences between the
two hospitals in each country are just as big as those be-
tween hospitals in different countries. When subdividing
the patients into four types according to site and stage of
disease, the spread between the hospitals becomes even
wider. No hospital is consistently above or below the aver-
age resource use for all patient categories.
CONCLUSIONS: Superficial comparisons of the costs of
treating specific diseases in different countries will unavoid-
ably be confounded by differences in prices. By using a sin-
gle set of unit prices for weighting the use of resources, an
index reflecting only real differences in resource use may be
determined and used for initial, aggregate comparisons ex-
ploring the need for further analysis.
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ESTIMATING SURVIVAL GAIN FOR 
COST-EFFECTIVENESS ANALYSIS: THE 
EXAMPLE OF EARLY HORMONAL TREATMENT 
IN LOCALLY ADVANCED PROSTATE CANCER
Neymark N, Adriaenssen I, Caleo S
EORTC Health Economics Unit, Brussels, Belgium
OBJECTIVES: To examine the impact of various meth-
ods of estimating survival gain from censored survival
data on the results of a cost-effectiveness analysis.
METHODS: A cost-effectiveness analysis of the addition
to radiotherapy of early hormonal therapy with a LHRH
analogue (goserelin) in patients with locally advanced
prostate cancer has been carried out. The clinical results
derive from a randomized controlled trial (EORTC
22863, reported by Bolla et al. [1]), and resource utiliza-
tion data were collected retrospectively in one French
hospital recruiting 90/415 patients in the trial. Costs are
calculated from the viewpoint of the French health insur-
ance system. To estimate average survival, various meth-
ods are available and will be compared, notably a re-
stricted means analysis truncated at a median follow-up
of 45 months and extrapolations based on fitting a para-
metric model (e.g., Weibull or exponential) to the sur-
vival curves.
RESULTS: The clinical trial documented an overall sur-
vival rate at 5 years of 79% in the group receiving radio-
therapy plus hormonal therapy compared to 61% (p 
0.001) in those receiving only radiotherapy. The average
costs in the two groups were 81,700 FF and 69,900 FF
respectively. The survival improvement is thus associated
with an increase of 11,800 FF in average cost, but to de-
termine the incremental cost-effectiveness ratio (ICER)
the exact gain in average survival must be known. The re-
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sults of using the various estimation methods will be pre-
sented and discussed at the meeting.
CONCLUSIONS: Survival data from clinical trials are
normally not analyzed with the purpose of determining
average survival, but such estimates are necessary for
economic evaluation. Due to censoring, mean survival
can not be estimated without extrapolation or without
truncation in a restricted means analysis. The results in
terms of ICER will vary according to the estimation
method used. These variations should be examined in
sensitivity analyses
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METASTATIC BREAST CANCER PATIENTS 
TREATED WITH DOCETAXEL
Burrell A1, Hall A2, Eggleton SPH1
1Rhône-Poulenc Rorer, Kent, UK; 2Centre for Medical and 
Dental Education, St Bartholomew’s Hospital, London, UK
OBJECTIVE: QuOLA-T was established as a real-life UK
outcomes audit to measure changes in Quality of Life (us-
ing the EORTC QLQ-C30 questionnaire) in patients with
metastatic breast cancer treated with docetaxel (Taxo-
tere®) outside the parameters of formal clinical trials.
METHODS: QuOLA-T is an ongoing programme in
which Quality of Life (QoL), clinical parameters of perfor-
mance status (Karnofsky Index) and response data are col-
lected at baseline and after every two cycles of treatment
and following chemotherapy. Demographic parameters
are also collected at baseline. Evaluable patients were de-
fined as those for whom a baseline registration and QoL
form have been received, details of chemotherapy are com-
pleted and at least one QoL form from the treatment phase
has been received. Non-evaluable patients were those still
receiving treatment and those not meeting the criteria
above. There were no significant differences between eval-
uable and non-evaluable patients in any of the parameters
at baseline, indicating that evaluable patients are a fair
representation of the entire data set.
RESULTS: The median number of cycles of Taxotere ad-
ministered: 5 (range 1–9). 103 patients completed planned
chemotherapy (49%), with a median of 6 cycles. Major
reason for withdrawal from treatment was progressive dis-
ease (25%), median number of cycles: 4. There were sig-
nificant detrimental intra-patient changes in two of the
QLQ-C30 domains (Fatigue and Diarrhea) but there were
significant beneficial intra-patient changes in four of the
domains (Emotional Functioning, Pain, Constipation and
Nausea and Vomiting).
CONCLUSIONS: This is the first large prospective Qual-
ity of Life monitoring programme conducted in an unse-
lected population of patients with metastatic breast cancer
using a recognized instrument. The hypothesis that quality
of life is significantly decreased during the active phase of
chemotherapy with Taxotere is not supported. This study
provides a much clearer picture of the real-life effects of
Taxotere on Quality of Life.
CA5
QUALITY OF LIFE IN A BREAST
CANCER POPULATION UNDERGOING 
ADJUVANT TREATMENT
Nichol MB1, Venturini F1, Jones J1, Sherman G2
1University of Southern California, Los Angeles, CA, USA; 
2Cancer Care Associates, Torrance, CA, USA
OBJECTIVE: To investigate the effect of adjuvant breast
cancer therapy on quality of life, and to evaluate the oc-
currence of dose delay or reduction by type of therapy.
MATERIALS AND METHODS: The study population
was drawn from patients treated by a major oncology cen-
ter in Southern California. The inclusion criteria were: fe-
males 18 years old or older treated with adjuvant therapy,
with stage I, II or III non-metastatic breast cancer. Partici-
pants were sent up to five surveys: one before treatment ini-
tiation, two or three (depending on the number of cycles) at
regular intervals between treatments, and a final one 4
weeks after the end of the chemotherapy session. The survey
contained two quality of life instruments: the SF-36 and the
Breast Cancer Chemotherapy Questionnaire (BCQ).
RESULTS: At the beginning of the chemotherapy course,
40 patients were prescribed CMF (48.2%), 24 AC
(28.9%), 11 A-CMF sequential (13.3%), and 8 other regi-
mens (9.6%). Average values for the physical component
summary score (PCS) of the SF-36 did not vary over time,
ranging from 42.1 to 46.1. The mental component sum-
mary score (MCS) had a peak at mid-point (48.1), while it
stabilized to the initial value at the end of the therapy
(46.8 vs. 46.5). Comparisons of the difference between the
baseline quality of life scores and a summary measure of
the subsequent scores among treatment groups were not
significant. Correlation coefficients showed that, at each
period, MCS score was highly correlated with the disease-
specific BCQ score (correlation coefficients from 0.69 to
0.81, p  0.001). During the chemotherapy course, 32 pa-
tients experienced a dose delay, 12 a dose reduction and 9
prematurely terminated their chemotherapy regimen, with
no difference among treatment groups.
DISCUSSION: The MCS of the SF-36 was highly correlated
with the disease specific instrument, while the PCS was not.
QUALITY OF LIFE STUDY RESULTS
QL1
THE QUALITY OF LIFE OF ESSENTIAL 
HYPERTENSIVES IN AN ECONOMICALLY 
DISADVANTAGED COMMUNITY:
PREDICTORS AND RELEVANCE TO 
MANAGEMENT COMPLIANCE
Golubev SA, Miliy MN, Shumann SG
Vitebsk State Medical University, Vitebsk, Belarus
OBJECTIVES: To evaluate the quality of life (QL) in es-
sential hypertensives (EH) of Belarus, a European country
with a unique combination of the important rise in cardio-
vascular morbidity and mortality, highly restricted financ-
